anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a lipstick molding device that can automatically fill, mold, and draw out lipstick material. Currently, when errors occur during an automatic process of filling lipstick material or drawing out a lipstick, a user has to stop the entire device in order to replace a mold. The mold replacement is manually performed so that productivity is reduced and costs are increased. To solve this, provided is a lipstick molding device comprising: a filling unit for filling lipstick raw material in a mold; and a lipstick drawing out unit for drawing out a filled lipstick. The mold (10) is settled on a rotating turn table (11) in order to rotate. A mold replacing means (80) is equipped at one side of the lipstick drawing out unit (60) so as to draw out the error-generated mold (10) in order to be replaced by a new mold (10). Accordingly, despite the errors that occur during a work process, only the corresponding mold can be automatically replaced without stopping the entire device, so that productivity is improved and costs are remarkably reduced.
BACKGROUND: Magnetic resonance imaging (MRI) may be useful in detecting labyrinthitis and thereby predicting the development of sensorineural hearing loss (SNHL) in adults with central nervous system (CNS) infections. We therefore investigated the coherence between brain MRI and SNHL among adults with CNS infections.
METHODS: Twenty-eight patients with bacterial or viral meningitis, viral encephalitis, or Lyme neuroborreliosis, who had a brain MRI during the acute disease and pure-tone audiometry at follow-up, were included. Neuroradiologists were blinded to the audiometric outcome when rating each inner ear for MRI cochlear gadolinium enhancement using a postcontrast T1-weighted (T1W) sequence and signal intensity using a fluidattenuated inversion recovery (FLAIR) sequence. Scores were compared to the degree of SNHL.
RESULTS: Sensorineural hearing loss was observed in all types of infection, affecting 14 patients (26 of 56 ears). Enhancement on T1W was detected in 1 ear with normal hearing. Fluid-attenuated inversion recovery signal intensity was detected in 26 of 50 ears, of which 12 developed SNHL. The sensitivity of T1W could not be calculated. Fluid-attenuated inversion recovery had a sensitivity of 50% and specificity of 46%.
CONCLUSION: Standard brain MRI protocols are not sufficient for the detection of labyrinthitis leading to SNHL following infection of the CNS.
A system includes a scleral prosthesis and an insert. The scleral prosthesis includes a first end configured to be pulled through a scleral tunnel in an eye and a second end. Each end is wider than a middle portion of the scleral prosthesis. Two portions form the first end of the scleral prosthesis, and the portions are separated along at least half of a length of the scleral prosthesis. The scleral prosthesis is formed from a single integrated piece of material. The second end is undivided. The insert is configured to be placeable between the two portions. The two portions may be separated from one another without external interference, and the two portions may be configured to be pushed towards each other in order to reduce a width of the first end and then separate after release.
Caution should be exercised in the handling and preparation of solutions of CellCept Intravenous. Avoid direct contact of the prepared solution of CellCept Intravenous with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water (see WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and HANDLING AND DISPOSAL).

CellCept Intravenous does not contain an antibacterial preservative; therefore, reconstitution and dilution of the product must be performed under aseptic conditions. Additionally, this product is sealed under vacuum and should retain a vacuum throughout its shelf life. If a lack of vacuum in the vial is noted while adding diluent, the vial should not be used.

CellCept Intravenous infusion solution must be prepared in two steps: the first step is a reconstitution step with 5% Dextrose Injection USP, and the second step is a dilution step with 5% Dextrose Injection USP. A detailed description of the preparation is given below:

Step 1

  * a)Two (2) vials of CellCept Intravenous are used for preparing each 1 g dose, whereas three (3) vials are needed for each 1.5 g dose. Reconstitute the contents of each vial by injecting 14 mL of 5% Dextrose Injection USP.
  * b)Gently shake the vial to dissolve the drug.
  * c)Inspect the resulting slightly yellow solution for particulate matter and discoloration prior to further dilution. Discard the vials if particulate matter or discoloration is observed.



Step 2

  * a)To prepare a 1 g dose, further dilute the contents of the two reconstituted vials (approx. 2 × 15 mL) into 140 mL of 5% Dextrose Injection USP. To prepare a 1.5 g dose, further dilute the contents of the three reconstituted vials (approx. 3 × 15 mL) into 210 mL of 5% Dextrose Injection USP. The final concentration of both solutions is 6 mg mycophenolate mofetil per mL.
  * b)Inspect the infusion solution for particulate matter or discoloration. Discard the infusion solution if particulate matter or discoloration is observed.



If the infusion solution is not prepared immediately prior to administration, the commencement of administration of the infusion solution should be within 4 hours from reconstitution and dilution of the drug product. Keep solutions at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

CellCept Intravenous should not be mixed or administered concurrently via the same infusion catheter with other intravenous drugs or infusion admixtures.
A heat-plastic material for use in making dentures comprises a previously polymerized tough styrol, obtained, for instance, by the methods disclosed in Specifications 236,891 and 243,768, [both in Class 2 (iii), Dyes &c.], or any suitable polymer of styrol homologues in admixture with a maximum of 15 per cent of a siliceous material such as that known under the registered Trade Mark "Asbestine", aglaite, talc, or a diatomaceous earth such as celite. A red colouring matter, such as cadmium selenide, and 0.5-2 per cent of a pigment such as lithopone, titanium oxide, zinc sulphide, or zinc oxide may also be present.  The admixture is preferably obtained by adding the other ingredients to a 30-60 per cent solution of the polymerized styrol in a solvent such as ethyl benzol, which is subsequently driven off.  The material is powdered and used as such, or cast into blanks at 120-160 DEG  C. under a pressure of 300-500 lbs. per sq. in.  A composition giving a mottled effect is obtained by producing two batches, one having more red colouring matter than the other, and mixing the two in powdered form prior to moulding. The less coloured may be rendered opaque rather than translucent.ALSO:A denture is formed by moulding an admixture of previously polymerized tough styrol, obtained, for instance, by the methods disclosed in Specifications 236,891 and 243,768, [both in Class 2 (iii), Dyes &c.], or any suitable polymer of styrol homologues with siliceous material, such as that known under the Registered Trade Mark "Asbestine," or aglaite, diatomaceous earth such as celite, or talc, a maximum of 15 per cent being specified. The mixture preferably also contains a red colouring matter, for example, cadmium selenide, and 0,5-2 per cent of a filler such as lithopone, titanium oxide, zinc sulphide, or zinc oxide.  The admixture is preferably obtained by adding the other ingredients to a 30-60 per cent solution of the polymerized styrol in a solvent such as ethyl benzol which is subsequently driven off. The material is powdered and converted into blanks at 120-160 DEG  C. under a pressure of 300-500 lbs. per sq. in.  A composition giving a natural mottled appearance is obtained by producing two batches, one having more red colouring-matter than the other, and mixing the two in powdered form prior to moulding.  The less coloured may be rendered opaque rather than translucent.  In preparing the denture, a wax model complete with porcelain teeth is set up in a two-part plaster of Paris mould.  The sections are backed with metal, the wax melted out, and the cavity filled with the admixture in the form of powder or blanks, sufficient being used to form a small amount of flash. The denture is moulded at from 300-350 DEG  F. under a pressure of 400-800 lbs., cooled slowly and finally in water.  When cold, the denture is finished in the usual manner.
The invention relates to a medicinal composition for treating cancer and use thereof and belongs to the field of chemical medicaments. To solve the technical problem, the invention provides a medicinal composition for treating cancer. The medicinal composition for treating cancer comprises the following active ingredient of tetravalent V inorganic acid salt. Compared with like medicaments in market, the medicament has the advantages of obviously reducing the cost and lightening economical burden of a patient. Clinical researches prove that: the medicament does not have obvious toxic or side effect or increase pain to the body of the patient. The medicament has higher recovery rate, is a new option for treating the cancer, and has wide market prospect.
Monitoring apparatus and methods are provided for assessing a physiological condition of a subject. At least two types of physiological information are detected from a subject via a portable monitoring device associated with the subject, and an assessment of a physiological condition of the subject is made using the at least two types of physiological information, wherein each type of physiological information is individually insufficient to make the physiological condition assessment. Environmental information from a vicinity of a subject also may be detected, and an assessment of a physiological condition of the subject may be made using the environmental information in combination with the physiological information. Exemplary physiological information may include subject heart rate, subject activity level, subject tympanic membrane temperature, and subject breathing rate. Exemplary environmental information may include humidity level information in the vicinity of the subject. An exemplary physiological condition assessment may be subject hydration level.
Although the precise mechanism of action of hydrALAZINE is not fully understood, the major effects are on the cardiovascular system. HydrALAZINE apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. HydrALAZINE, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.

The peripheral vasodilating effect of hydrALAZINE results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. HydrALAZINE usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. HydrALAZINE also maintains or increases renal and cerebral blood flow.

HydrALAZINE hydrochloride is rapidly absorbed after oral administration, and peak plasma levels are reached at 1 to 2 hours. Plasma levels of apparent hydrALAZINE decline with a half-life of 3 to 7 hours. Binding to human plasma protein is 87%. Plasma levels of hydrALAZINE vary widely among individuals. HydrALAZINE is subject to polymorphic acetylation; slow acetylators generally have higher plasma levels of hydrALAZINE and require lower doses to maintain control of blood pressure. HydrALAZINE undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.
Non-CF control males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter\^2) of ChapStick Active Performance (CAP) Unscented will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
A pyridopyrimidine or naphthyridine derivative represented by the general formula (I) (I) (wherein R1 is optionally substituted nitrogenous heterocyclic group, etc.; R2 is hydrogen or lower alkyl; R3 is hydrogen, optionally substituted lower alkyl, etc.; R4 is hydrogen, lower alkyl, COOH, etc.; R5 is hydrogen, optionally substituted aryl, etc.; and one of X and Y is CH and the other is nitrogen, or both of X and Y are nitrogen); or a pharmacologically acceptable salt of the derivative. They have excellent PDE V inhibitory activity and are useful as a preventive/remedy for erectile dysfunction.
BACKGROUND AND AIMS: H-type hypertension is essential hypertension combined with high homocysteine, and both synergistically increase the risk of cardiovascular and cerebrovascular events. The aim of this study was to investigate the risk factors of H-type hypertension in Tibetan plateau population and correlation with MTHFR C677T gene.
METHODS AND RESULTS: A multi-stage cluster random sampling method was used to select the research subjects in Tibet Autonomous Region from June 2020 to November 2021. Among Tibetans, the incidence of H-type hypertension accounted for 84.31% of hypertensive patients. The logistic regression analysis demonstrated that age, uric acid (UA), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) were risk factors for the prevalence of H-type hypertension, the OR (95% CI) was 1.083(1.073-1.094), 1.002(1.001-1.004), 1.240(1.050-1.464) and 2.274(1.432-3.611), respectively. MTHFR C677T TT genotype patients with H-type hypertension OR (95% CI) was 1.629(1.004-2.643). Based on this, a nomogram model was established, and the reliability of the model was proved by area under ROC curve, Brier score and average absolute error. The model's results indicate that for every five years of age, the score increases by 6 points; for a 2mmol/L increase in TG, the score increases by 5.5 points; for a 1mmol/L increase in LDL-C, the score increases by 10 points; and individuals with the TT genotype receive 8 points. The higher the score, the greater the risk of disease.
CONCLUSION: The MTHFR C677T TT genotype is a risk locus for Tibetan patients with H-type hypertension, with age, TG, and LDL-C were identified as risk factors for the disease.
NEW MATERIAL:The phospholipid A contg. choline having the following characteristics: colorless oily substance; molecular weight, 805 and 831 by FD-MS and SIMS; soluble in ether, methanol, etc., insoluble in acetone and water; positive to Dragendorff reagent, Dittmer-Lester reagent, etc.; negative to H2SO4, ninhydrin reagent, etc. USE:Carcinostatic agent. PROCESS:The embryo of a rainbow trout (salma gairdneri) of 12-14 days after fertilization is homogenized, and extracted successively with acetone, ether, and a chloroform-methanol mixture. The extracts are mixed to together, concentrated in vacuum, and developed by silica gel column chromatography. The active component existing in the chloroform-methanol fraction is purified to obtain the phospholipid A. The objective drug having excellent carcinostatic activity and low toxicity can be obtained by using the phospholipid A as an active component. Dose: 0.01-100mg/kg daily for oral administration and <= about 10mg/kg daily for parenteral administration.
We believe that the risks of allogeneic transplant can be drastically reduced if the following criteria can be met: (1) consistent engraftment, (2) little or no GVHD with the ability to rapidly withdraw immune suppression, (3) rapid recovery of CD4 counts to levels greater than 200 cells/micro liter. Our prior (ongoing) trial attempts to address how LLME treated T cells given as donor lymphocyte infusion (DLI) can address points 2 and 3 above. The current study addresses how treatment of the CD34- fraction of the graft attempts to address points 1 and 2 (and to a lesser extent point 3) above. We believe that if these points can be consistently achieved that the mortality of allogeneic HSCT may be reduced to levels more akin to those of autologous HSCT. We propose to test the hypothesis that LLME-treated T cells will be safe with regard to reducing GVHD or other infusion related toxicities and that their administration as part of the transplant will facilitate engraftment. We believe that this approach will ultimately be an important step in a variety of transplant settings ranging from matched siblings to haplodisparate donors.
PURPOSE: To obtain the subject preparation containing the salt of L-carnitine with L-tartaric acid and stable for a long period. CONSTITUTION: This preparation contains the salt of L-carnitine with L-tartaric acid. The L-carnitine plays an important role on the metabolism of fats and is especially used as a sport nutrient or for the therapy of patients having fat metabolism disorders. The salt of the L-carnitine with the L-tartaric acid is stable in an usual air humidity for a long period, exhibits less hygroscopicity, is good in processability because of being free from both agglomerating and adhering properties, and is especially suitably processed with a high-speed rotated machine. The salt of the L-carnitine with the L-tartaric acid is perfectly odorless and exhibits a fresh sour taste due to the combination of the tartaric acid. The salt of the L-carnitine with the L-tartaric acid is used in the form of tablets, capsules or powdery enteric preparations.
Disclosed are a bifunctional protein degradation-targeted chimera compound, a preparation method therefor and medicinal use thereof. In particular, the present invention relates to a compound as shown by general formula (I), a preparation method therefor and use thereof for degrading and inhibiting an FLT3 tyrosine protein kinase, particularly for preventing and/or treating human diseases including cancers. One end of the compound contains a group that binds to an E3 ubiquitin ligase, and the other end contains a group that binds to an FLT3 tyrosine protein kinase. Connecting by a linker can enable FLT3 to be located near the ubiquitin ligase. The compound shows a wide range of pharmacological activities consistent with dual functions of degrading and inhibiting the FLT3 tyrosine protein kinase. The definition of each group in general formula (I) is the same as the definition in the description.
BACKGROUND: Early features of multiple system atrophy (MSA) are similar to those in Parkinson's disease (PD), which can challenge differential diagnosis. Identifying clinical markers that help distinguish MSA from forms of parkinsonism is essential to promptly implement the most appropriate management plan. In the context of a thorough neurological evaluation, the presence of a vocal flutter might be considered a potential feature of MSA-parkinsonian type (MSA-P).
CASES: This case series describes clinical histories of 3 individuals with MSA-P. In each case, vocal flutter was detected during neurological and motor speech evaluations. It seemed to be a concomitant feature with the constellation of other signs and symptoms that led to the clinical diagnosis.
LITERATURE REVIEW: The vocal flutter may be described as pitch and loudness fluctuations during phonation. Different from a vocal tremor, the flutter phenomenon has higher oscillation frequencies. The neuropathological underpinnings of vocal flutter may be related to generalized laryngeal dysfunction that is commonly described in MSA-P.
CONCLUSION: Vocal flutter may be a unique speech feature in some individuals who have MSA-P. Future studies using perceptual and acoustic measures of speech are warranted to quantify these observations and directly compare to other MSA variants, PD, and a control group.
Overeating leads to overweight and obesity. Effective eating regulation largely depends on an individual's responsiveness to internal cues of physiological hunger and satiety; this phenomenon is known as interoceptive awareness and has been shown to be lower in individuals with overweight or obesity. Mindfulness training may improve interoceptive awareness and thus may facilitate more effective regulation of eating through increased sensitivity to cues of hunger and fullness. Mindful eating programs have been shown to increase interoceptive awareness of hunger and satiety cues and decrease weight in individuals with obesity. Although these programs are effective, they involve lengthy group sessions, require extensively trained staff, and are not widely available outside of clinical research. Thus, the reach and impact of these programs are limited.

The present study developed and tested a brief mindful eating intervention inspired by Kristeller \& Wolever's (2010) Mindfulness-Based Eating Awareness Training program to increase interoceptive awareness in individuals with overweight and obesity as a means to increase mindful and intuitive eating, reduce overeating and facilitate weight loss. The program consisted of 9 weekly 10-15 minute sessions structured around one simple evidence-based mindful eating exercise, and was delivered to adult (ages 18-67) employees from a Canadian university.
Presented are apparatus and methods for providing online health monitoring and accumulating data from patients applicable in both diagnosing and prescribing preventive medical treatment. Methods and devices include using a sensitive acoustic device to analyze a patient's health function from a location such as a public computer kiosk, a doctor's office or a patient's computer. The data may be downloaded to a central database, for example, via the Internet. The data may be retrieved by the patient, or accessed by doctors for purposes of diagnosis, monitoring and treatment. The data may include demographic data that can be stored while maintaining patient anonymity. The data may be accessible to researchers providing medical statistics on a wide variety of patients from various age groups, ethnic backgrounds, medical histories and the like.
Perioperative clinical routine data are going to be assessed as per standard. Postoperatively, a standardized lung sonography is going to be performed in the recovery room. Patients will then be visited on the ward on postoperative day 1, 3 and 7 for clinical examination to detect postoperative pulmonary complications according to the criteria elaborated by the StEP- collaboration.